Increasing HPV Vaccine Coverage among Young Adult Gay and Bisexual Men

提高年轻男同性恋和双性恋男性的 HPV 疫苗覆盖率

基本信息

批准号：
9096774
负责人：
Annie-Laurie McRee
金额：
$ 16.78万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-07-01 至 2018-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9096774
关键词：
Address Affect Age Annual Reports Anogenital Human Papilloma Virus Infection Anogenital venereal warts Applications Grants Area Bisexual Control Groups Data Disease Dose Gays General Population Genital system Goals Guidelines Health Healthy People 2020 Heterosexuals Human Papilloma Virus Vaccination Human Papilloma Virus Vaccine Human Papillomavirus Human papilloma virus infection Incidence Interdisciplinary Study Intervention Lesbian Gay Bisexual Licensing Malignant neoplasm of anus Malignant neoplasm of penis Mediator of activation protein Motivation Outcome Participant Pilot Projects Population President&apos s Cancer Panel Prevalence Provider Randomized Randomized Controlled Trials Recommendation Recruitment Activity Reporting Research Research Priority Sampling Series Sexually Transmitted Diseases Surveys Target Populations Testing United States Vaccination Vaccine Research base cancer type design disparity reduction effective intervention efficacy testing follow-up group intervention high risk improved mHealth male malignant oropharynx neoplasm meetings men men who have sex with men novel preference primary outcome public health priorities response satisfaction secondary outcome social media theories transgender web site young adult

项目摘要

DESCRIPTION (provided by applicant): Gay and bisexual men have high rates of human papillomavirus (HPV) infection and HPV-related disease (e.g., anal cancer) compared to the general population. HPV vaccination is a promising strategy for reducing these existing disparities, as routine HPV vaccination is recommended for young gay and bisexual men (YGBM) through age 26. However, little research has addressed HPV vaccination among YGBM, and no interventions we are aware of have been developed specifically for this high-risk population. To address this important research gap, we conducted a national survey of YGBM ages 18-26 in late 2013. Only about 13% of participants had received any doses of HPV vaccine, and results provided valuable information for designing an HPV vaccine intervention for YGBM. Based on results of this preliminary research, an interdisciplinary research team will conduct the proposed study, "Increasing HPV Vaccine Coverage among Young Adult Gay and Bisexual Men." The study will develop and pilot test a theoretically-based mobile health (mHealth) HPV vaccine intervention for YGBM that will consist of: 1) population-targeted, individually-tailored content about HPV and HPV vaccine; and 2) vaccination reminders. During pilot testing, the intervention will be compared to a control group that receives standard information about HPV and HPV vaccine via a mobile-friendly website. The study will have two primary aims and an exploratory aim. Aim 1 will develop and pilot test the mHealth HPV vaccine intervention for YGBM to establish intervention feasibility and acceptability. Feasibility will be established by meeting recruitment (n=94) and retention (85% retention over a 6-month follow-up period) goals for the pilot study, and acceptability will be established by comparing participant satisfaction with study materials between the intervention and control groups. Aim 2 will obtain preliminary efficacy data on whether the mHealth HPV vaccine intervention increases HPV vaccine initiation compared to the control group. HPV vaccine initiation (i.e., receipt of the first dose of the three-dose HPV vaccine series) will serve as the primary outcome for the pilot study. An exploratory aim will examine whether the mHealth HPV vaccine intervention affects secondary outcomes compared to the control group. Secondary outcomes will include receipt of the second and third doses of the HPV vaccine series and changes in potential mediators between study group and HPV vaccination. Results from the pilot study will establish intervention feasibility and acceptability and provide valuable preliminary data on outcomes related to HPV vaccination. These data will inform an R01 grant application to test the efficacy of the mHealth HPV vaccine intervention in a large randomized controlled trial.

描述（由应用提供）：与普通人群相比，同性恋和双性恋男性的人乳头瘤病毒（HPV）感染和HPV相关疾病（例如，肛门癌）的率很高。 HPV疫苗接种是减少这些现有分布的一种有前途的策略，因为通常建议年轻的同性恋和双性恋男性（YGBM）在26岁之前进行常规的HPV疫苗接种。但是，很少有研究涉及YGBM中的HPV疫苗接种，并且我们没有针对这种高风险的人才开发的干预措施。为了解决这一重要的研究差距，我们在2013年底对18-26岁的YGBM进行了全国调查。只有约13％的参与者收到了任何剂量的HPV疫苗，结果为设计HPV疫苗干预的YGBM提供了宝贵的信息。根据这项初步研究的结果，跨学科研究小组将进行拟议的研究，“增加了年轻的成人同性恋和双性恋男性的HPV疫苗覆盖范围”。该研究将开发和试点测试YGBM的理论上基于理论上的移动健康（MHPV）HPV疫苗干预措施，其中包括：1）涉及HPV和HPV疫苗的人口靶向，个人定制的内容； 2）疫苗提醒。在试点测试期间，将将干预措施与通过移动友好网站接收有关HPV和HPV疫苗的标准信息进行比较。该研究将具有两个主要目标和探索性目标。 AIM 1将开发和试点测试YGBM的MHealth HPV疫苗干预，以确定干预性和可接受性。可行性将通过满足招聘（n = 94），并保留（在6个月的随访期内保留85％的保留率）为试点研究，并通过比较参与者对干预组和对照组之间的研究材料的满意度来确定可接受性。 AIM 2将获得有关MHealth HPV疫苗干预是否与对照组相比的HPV疫苗倡议的初步效率数据。 HPV疫苗倡议（即，三剂量HPV疫苗系列的第一剂量的收到）将作为试点研究的主要结果。探索性目的将检查MHealth HPV疫苗干预是否会影响次要结果，将接收第二和第三剂量的HPV疫苗系列和研究组和HPV疫苗之间潜在介体的变化。试点研究的结果将建立干预性和可接受性，并提供有关与HPV疫苗有关的结果的有价值的初步数据。这些数据将在大型随机对照试验中告知R01赠款应用程序，以测试MHealth HPV疫苗干预的效率。